SynthesisRheumatology international2026
Psychiatric manifestation of neurosarcoidosis: a systematic review with pooled descriptive analysis of case reports and case series.
Synthesis in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurosarcoidosis is a rare inflammatory disease with a heterogeneous presentation. Psychiatric manifestations may precede neurological involvement, but their prevalence, diagnostic pattern, and treatment outcomes remain insufficiently defined. PubMed, Web of Science and Scopus databases were searched on July 8, 2025, to identify all published case reports reporting psychiatric manifestations in patients with sarcoidosis or neurosarcoidosis without language or publication year restriction. All relevant data were extracted based on study characteristics, patient demographics, clinical history, psychiatric and neurological manifestations, diagnostic investigations, treatment modalities, and clinical outcomes. Eighty-nine studies describing 93 patients' cases were included. The mean age was 45.48 ± 14.46 years, with a male predominance (58.1%). 74.2% had systemic sarcoidosis, while 25.8% presented with isolated neurosarcoidosis. Diagnosis was confirmed by histopathology in 84.9% of patients. Psychiatric symptoms preceded neurological manifestations in 78.5% of cases. The most common psychiatric manifestation was cognitive impairment followed by personality changes (88.2%, 65.6% respectively). MRI frequently showed parenchymal lesions (66.7%) and leptomeningeal enhancement (57.7%), while CSF analysis commonly revealed elevated protein (80%) and pleocytosis (71.3%). Corticosteroids were used in (93.5%) of patients, with 58.1% achieving complete remission. Acute psychiatric onset (48.1% vs. 15.4%, p = 0.002) and delirium (70.4% vs. 41.0%, p = 0.013) were observed with higher remission. Isolated neurosarcoidosis (33.3% vs. 16.7%, p = 0.040), parenchymal lesions (59.0% vs. 50.0%, p = 0.034) and basal ganglia involvement (30.8% vs. 16.7%, p = 0.045) were significantly more common among patients who did not achieve complete remission. Systemic sarcoidosis is more frequently linked with higher remission rates due to earlier recognition and less irreversible CNS damage. Neuropsychiatric presentations are heterogeneous, with delirium associated with favorable remission outcomes. Corticosteroids remain the mainstay of therapy. Further prospective studies are needed to phenotype and optimize management strategies. PROSPERO: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251140210 .
Indexed as
Identifiers
42762351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.